Drug intelligence / Profile preview

circCDUPRT

Development stage
Preclinical
Lead developer
Third Military Medical University
Modality
mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratumoral
01

Overview

circCDUPRT is an engineered circular RNA (circRNA) designed for gene-directed enzyme prodrug therapy (GDEPT). It encodes a fusion protein consisting of cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT). Delivered intratumorally via lipid nanoparticles (LNPs), the circRNA provides sustained expression of the CDUPRT enzyme within the tumor microenvironment. This enzyme facilitates the conversion of the non-toxic prodrug 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and its subsequent toxic metabolites, inducing localized tumor cell death while minimizing systemic side effects. Preclinical studies in melanoma models have demonstrated that circCDUPRT, especially when combined with IL-15-expressing circRNA, can significantly enhance the activation and expansion of CD8+ T cells and NK cells, offering a potent strategy for combined chemo-immunotherapy.

Other names
circular RNA encoding cytosine deaminase–uracil phosphoribosyltransferase
02

Targets

TS (Thymidylate synthase)FCU1 (FCU1 fusion protein)

Beyond the preview

Go deeper on circCDUPRT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on circCDUPRT.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call